Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: Year 1 results of the focus study - Commentary

Research output: Contribution to journalComment/debate

Original languageEnglish (US)
Pages (from-to)100-101
Number of pages2
JournalEvidence-Based Ophthalmology
Volume8
Issue number2
DOIs
StatePublished - Apr 2007

Fingerprint

Photochemotherapy
verteporfin
Ranibizumab
Macular Degeneration, Age-Related, 1

All Science Journal Classification (ASJC) codes

  • Ophthalmology
  • Sensory Systems

Cite this

@article{b1c2edf3e07745f7b04e2c50c6e4419b,
title = "Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: Year 1 results of the focus study - Commentary",
author = "Ingrid Scott",
year = "2007",
month = "4",
doi = "10.1097/IEB.0b013e31803c9ade",
language = "English (US)",
volume = "8",
pages = "100--101",
journal = "Evidence-Based Ophthalmology",
issn = "1555-9203",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration

T2 - Year 1 results of the focus study - Commentary

AU - Scott, Ingrid

PY - 2007/4

Y1 - 2007/4

UR - http://www.scopus.com/inward/record.url?scp=34247259994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247259994&partnerID=8YFLogxK

U2 - 10.1097/IEB.0b013e31803c9ade

DO - 10.1097/IEB.0b013e31803c9ade

M3 - Comment/debate

AN - SCOPUS:34247259994

VL - 8

SP - 100

EP - 101

JO - Evidence-Based Ophthalmology

JF - Evidence-Based Ophthalmology

SN - 1555-9203

IS - 2

ER -